Aptar Pharma’s Electronic Lockout Device Approved by EMA

Published on: 

Sponsored Content

Aptar Pharma’s e-Lockout device is the first and only fully integrated electronic nasal drug delivery device to be approved by a US or European regulatory authority.

Courtesy of Aptar Pharma


Aptar Pharma announced the approval by the European Medicines Agency (EMA) of the first integrated electronic nasal lockout device (e-Lockout) following a multi-year development with Takeda Pharmaceuticals International AG.



Aptar Pharma agreed to supply Takeda with its e-Lockout device for a multidose nasal spray version of Instanyl® used in pain management. The EMA has granted marketing authorization for this multidose nasal spray treatment under the name Instanyl DoseGuard™.


Takeda will launch Instanyl DoseGuard in Europe in several multidose strengths, using Aptar Pharma’s patented electronic lockout system. The approval represents a major milestone for Aptar Pharma, with the e-Lockout device being the first and only fully integrated electronic nasal drug-delivery device to be approved by EMA.


About Aptar Pharma


Aptar Pharma is part of AptarGroup, Inc. (NYSE: ATR), a leading global supplier of a broad range of innovative dispensing and sealing solutions for the beauty, personal care, home care, prescription drug, consumer health care, injectables, food and beverage markets. AptarGroup is headquartered in Crystal Lake, Illinois, with manufacturing facilities in North America, Europe, Asia and South America. For more information, visit:www.aptar.com/pharma


To download the complete press release: